- Home
- ENTA vs MAPS Comparison
ENTA vs MAPS Comparison
Compare ENTA & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- MAPS
- Stock Information
- Founded
- ENTA 1995
- MAPS 2008
- Country
- ENTA United States
- MAPS United States
- Employees
- ENTA N/A
- MAPS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- MAPS Computer Software: Prepackaged Software
- Sector
- ENTA Health Care
- MAPS Technology
- Exchange
- ENTA Nasdaq
- MAPS Nasdaq
- Market Cap
- ENTA 127.8M
- MAPS 119.8M
- IPO Year
- ENTA 2013
- MAPS N/A
- Fundamental
- Price
- ENTA $6.28
- MAPS $1.63
- Analyst Decision
- ENTA Buy
- MAPS Buy
- Analyst Count
- ENTA 4
- MAPS 2
- Target Price
- ENTA $19.50
- MAPS $2.61
- AVG Volume (30 Days)
- ENTA 537.1K
- MAPS 1.5M
- Earning Date
- ENTA 02-05-2025
- MAPS 11-12-2024
- Dividend Yield
- ENTA N/A
- MAPS N/A
- EPS Growth
- ENTA N/A
- MAPS N/A
- EPS
- ENTA N/A
- MAPS N/A
- Revenue
- ENTA $67,635,000.00
- MAPS $183,311,000.00
- Revenue This Year
- ENTA $11.80
- MAPS N/A
- Revenue Next Year
- ENTA $3.99
- MAPS $9.09
- P/E Ratio
- ENTA N/A
- MAPS N/A
- Revenue Growth
- ENTA N/A
- MAPS N/A
- 52 Week Low
- ENTA $5.70
- MAPS $0.70
- 52 Week High
- ENTA $17.80
- MAPS $1.64
- Technical
- Relative Strength Index (RSI)
- ENTA 31.04
- MAPS 69.88
- Support Level
- ENTA $5.70
- MAPS $1.07
- Resistance Level
- ENTA $6.56
- MAPS $1.56
- Average True Range (ATR)
- ENTA 0.74
- MAPS 0.14
- MACD
- ENTA -0.11
- MAPS 0.01
- Stochastic Oscillator
- ENTA 14.91
- MAPS 98.25
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.